BioMarin Pharmaceutical Inc.
_________________________________________________________________________________
BioMarin Pharmaceutical Inc. Financial Snapshot
Operating Performance
Fast Facts
105 Digital Drive, NOVATO, 94949,United The company reported revenue of US$441 million
Headquarters Address
States of America during the fiscal year 2011 (2011). The company's
revenue grew at a CAGR of 38.03% during 2007–
Telephone + 1 415 5066700
2011, with an annual growth of 17.30% over 2010. In
2011, the company recorded an operating margin of -
Fax + 1 415 3827889 8.11%, as against -3.50% in 2010.
Website www.bmrn.com
Revenue and Margins
Ticker Symbol, Stock Exchange BMRN, NASDAQ
Number of Employees 1,002
Fiscal Year End December
Revenue (in US$ million) 441
SWOT Analysis
Strengths Weaknesses
Collaborative Agreements Dependence on Third Parties
Impressive top line performance Geographic concentration
Strong patent portfolio
Opportunities Threats
Growing prevalence of cancer Intense competition
Product development pipeline Tightening regulations
Rising GDP outlook Uncertain R&D outcomes
___________________________________________________________________________________________
BioMarin Pharmaceutical Inc. - SWOT Profile Page 1
BioMarin Pharmaceutical Inc.
_________________________________________________________________________________
TABLE OF CONTENTS
1 Business Analysis ................................................................................................................................... 5
1.1 Company Overview ................................................................................................................................................5
1.2 Business Description ..............................................................................................................................................5
1.3 Major Products and Services .................................................................................................................................6
2 Analysis of Key Performance Indicators ............................................................................................... 7
2.1 Five Year Snapshot: Overview of Financial and Operational Performance Indicators ..........................................7
2.2 Key Financial Performance Indicators .................................................................................................................10
2.2.1 Revenue and Operating Profit .........................................................................................................................10
2.2.2 Asset and Liabilities .........................................................................................................................................11
2.2.3 Net Debt vs. Gearing Ratio ..............................................................................................................................12
2.2.4 Operational Efficiency ......................................................................................................................................13
2.2.5 Solvency ..........................................................................................................................................................14
2.3 Competitive Benchmarking ..................................................................................................................................15
3 SWOT Analysis ...................................................................................................................................... 16
3.1 SWOT Analysis - Overview ..................................................................................................................................16
3.2 Strengths ..............................................................................................................................................................16
3.3 Weaknesses .........................................................................................................................................................16
3.4 Opportunities ........................................................................................................................................................17
3.5 Threats .................................................................................................................................................................17
4 History .................................................................................................................................................... 19
5 Key Employees ...................................................................................................................................... 22
6 Key Employee Biographies................................................................................................................... 23
7 Locations and Subsidiaries .................................................................................................................. 24
7.1 Head Office ..........................................................................................................................................................24
7.2 Other Locations and Subsidiaries ........................................................................................................................24
8 Appendix ................................................................................................................................................ 25
8.1 Methodology .........................................................................................................................................................25
8.2 Ratio Definitions ...................................................................................................................................................25
8.3 Disclaimer.............................................................................................................................................................29
___________________________________________________________________________________________
BioMarin Pharmaceutical Inc. - SWOT Profile Page 2
BioMarin Pharmaceutical Inc.
__________________________________________________________________________________________
List of Tables
Table 1: Major Products and Services....................................................................................................................................6
Table 2: Key Ratios - Annual ..................................................................................................................................................7
Table 3: Key Ratios - Interim ..................................................................................................................................................9
Table 4: Key Capital Market Indicators ..................................................................................................................................9
Table 5: History.....................................................................................................................................................................19
Table 6: Key Employees .......................................................................................................................................................22
Table 7: Key Employee Biographies ....................................................................................................................................23
Table 8: Subsidiaries ............................................................................................................................................................24
Table 9: Locations ................................................................................................................................................................24
___________________________________________________________________________________________
BioMarin Pharmaceutical Inc. - SWOT Profile Page 3
BioMarin Pharmaceutical Inc.
__________________________________________________________________________________________
List of Figures
Figure 1: Revenue and Operating Profit ...............................................................................................................................10
Figure 2: Financial Position ..................................................................................................................................................11
Figure 3: Net Debt vs. Gearing Ratio ...................................................................................................................................12
Figure 4: Operational Efficiency ...........................................................................................................................................13
Figure 5: Solvency ................................................................................................................................................................14
___________________________________________________________________________________________
BioMarin Pharmaceutical Inc. - SWOT Profile Page 4
BioMarin Pharmaceutical Inc.
__________________________________________________________________________________________
1 Business Analysis
1.1 Company Overview
BioMarin Pharmaceutical Inc. (BioMarin) develops and commercializes innovative biopharmaceuticals for serious
diseases and medical conditions. Its principal product portfolio includes four approved products Naglazyme, Aldurazyme,
and Kuvan and Firdapse. The products that are under clinical trials are PEG-PAL, GALNS for Morquio Syndrome Type A
and BMN-701 for Pompe disease. The company also focuses on the development of BMN-673, PARP inhibitor for the
treatment of patients with cancer; BMN-673, PARP inhibitor for the treatment of patients with hema